Article thumbnail

When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?

By Tim L Jansen

Abstract

Over the past decades, more effective and less toxic biologicals have revolutionized rheumatology therapy in our battle against the autoimmune chronic inflammation of rheumatoid arthritis and spondyloarthropathy. But what about for patients who have previously had an infection of the liver? Prior hepatitis B virus infection clearly presents a challenge for clinicians. In a study by Charpin and colleagues of 21 patients whose hepatitis B virus serology suggested carrier status, anti-TNF treatment appeared to be safe during a limited follow-up period of 3 years. Studies are needed with longer follow-up, particularly in patients with low antibody titres (antiHBc). In the 3-year period, however, about 30% of the patients developed significant lowering of antibody titres, which may become relevant during long-term follow-up. Charpin and colleagues are the first to reveal promising data on the relative safety of anti-TNFs in a small series of hepatitis B carriers for up to 3 years

Topics: Editorial
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2875626
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). Chronic viral hepatitis and TNF blockade. Rheumatology (Oxford)
  2. (2004). E: Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology
  3. (2009). Gérolami R: Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther
  4. (2006). GH: Tumor necrosis factor inhibitors for rheumatoid arthritis.
  5. KJ: Acute viral hepatitis. In Harrison‘s Principles of Internal Medicine. Volume 2. 16th edn. Edited by
  6. (2007). Lok AS: Management of hepatitis B: summary of a clinical research workshop. Hepatology
  7. (1976). Merigan TC: Eff ect of leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.
  8. (1982). Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med
  9. (1991). Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology